RIGEL PHARMACEUTICALS INC
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) is a biotechnology company dedicated to developing and commercializing novel therapies for patients with hematologic disorders and cancer. The company focuses on products that address signaling pathways critical to disease mechanisms. More information is available at… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What RIGEL PHARMACEUTICALS INC does
In the company’s own words
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) is a biotechnology company dedicated to developing and commercializing novel therapies for patients with hematologic disorders and cancer. The company focuses on products that address signaling pathways critical to disease mechanisms. More information is available at www.rigel.com.
Rigel operates as a commercial-stage biopharmaceutical company with three FDA-approved products generating revenue. TAVALISSE (fostamatinib disodium hexahydrate) is an oral spleen tyrosine kinase inhibitor approved for treating adult patients with chronic immune thrombocytopenia who have had insufficient response to previous treatments. The product is also commercially available in Europe, the United Kingdom, Japan, Korea, Canada, and Israel. REZLIDHIA (olutasidenib) is an oral, small molecule drug indicated for adult patients with relapsed or refractory acute myeloid leukemia with isocitrate dehydrogenase-1 mutations. GAVRETO (pralsetinib) is a once-daily oral kinase inhibitor approved for metastatic RET fusion-positive non-small cell lung cancer and advanced or metastatic RET fusion-positive thyroid cancer in patients twelve years and older.
The company's development pipeline includes R289, a dual interleukin receptor-associated kinases 1 and 4 inhibitor being evaluated in a Phase 1b study for lower-risk myelodysplastic syndrome. Rigel also maintains strategic collaborations with the University of Texas MD Anderson Cancer Center and the Collaborative Network for Neuro-Oncology Clinical Trials to expand olutasidenib evaluation in additional disease areas, and partners with Eli Lilly and Company on a receptor-interacting serine/threonine-protein kinase 1 inhibitor program.
The company has established international partnerships for commercialization of its products, including agreements with Grifols for Europe and certain other territories, Kissei for Japan and Korea, Medison for Canada and Israel, and Knight for Latin America. Rigel maintains a fully integrated commercial organization in the United States focused on hematologists and hematologist-oncologists, supported by specialty pharmacy distribution channels and a patient support program called Rigel OneCare.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1034842
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns RIGEL PHARMACEUTICALS INC — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · RIGEL PHARMACEUTICALS INC’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do RIGEL PHARMACEUTICALS INC and its peers compare on margins and cash generation over ten years?”
- “Where did five years of RIGEL PHARMACEUTICALS INC's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in RIGEL PHARMACEUTICALS INC's last four quarterly filings that the numbers alone won't show?”